Mehrdad Abedi, M.D.

Mehrdad Abedi, M.D.

Specialties

Cancer

Hematology/Oncology

Internal Medicine

Department

Internal Medicine

Title

  • Professor

Reviews

To see if Mehrdad Abedi is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).

UC Davis Comprehensive Cancer Center

2279 45th Street
Sacramento, CA 95817
Driving Directions

Primary Phone:
800-362-5566
916-734-5959

Additional Phone Numbers

Clinic Phone: 916-734-5981
Clinic Fax: 916-734-0631
Physician Referrals: 800-4-UCDAVIS (800-482-3284)

Clinical Interests

Dr. Abedi's clinical interest is in the area of bone marrow transplantation and in the treatment of refractory/relapsed hematological malignancies.

Research/Academic Interests

Dr. Abedi's basic science research interest is in the area of hematopoietic stem cells and novel models of bone marrow transplantation.

Division

Hematology and Oncology

Center/Program Affiliation

UC Davis Comprehensive Cancer Center
Transplant Center

Education

M.D., Tehran University of Medical Sciences, Tehran, Iran 1991

Internship: Internal Medicine, Yale University/Bridgeport Hospital, New Haven CT 1996-1999

Residency

Internal Medicine, Yale University/Bridgeport Hospital, New Haven CT 1999

Fellowships

Hematology/Oncology, Brown University, Roger Williams Medical Center, Providence RI 2001-2002

Hematology/Oncology, University of Massachusetts Medical Center, Worcester MA 1999-2001

Board Certifications

American Board of Internal Medicine,

American Board of Internal Medicine, Medical Oncology,

Hematology Certification,

Professional Memberships

American Society for Blood and Marrow Transplantation (ASBMT)

American Society of Hematology (ASH)

Society for Hematology and Stem Cells (ISEH)

Honors and Awards

Alpha Clinic Award, UCDH, 2017

Select Recent Publications

For a comprehensive list of Dr. Abedi's publications, please click here (opens new window).

Hoeg RT, Davis J, Jonas BA, Tuscano J , Rosenberg A, Abedi M. A Phase I Study of Everolimus and Bendamustine in Patients With Relapsed/Refractory Lymphoid Hematologic Malignancies. Clinical Lymphoma, Myeloma & Leukemia. 2020 July;20(7):453-458. Doi:10.1016/j.clml.2020.2.006.

Tomlinson BK, Tuscano JM, Abedi M, Welborn J, Arora M, O'Donnell RT, Wun T, Jonas BA. A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia. Am J Hematol. 2019 Nov;94(11):e291-294. doi:10.1002/ajh.25605. Epub 2019 Aug 20.

Jamieson CHM, Millan MT, Creasey AA, Lomax G, Donohoe ME, Walters MC, Abedi M, Bota DA, Zaia JA, Adams JS. CIRM Alpha Stem Cell Clinics: Collaboratively Addressing Regenerative Medicine Challenges. Cell Stem Cell. 2018 Jul 1;22(6):801-805. doi:10.1016/j.stem.2018.05.007. PMID:29859170.

Pai, CS, Khuat, LT, Chen, M, Murphy, WJ, Abedi, M. Therapeutic Effects of a NEDD8-Activating Enzyme Inhibitor, Pevonedistat, on Sclerodermatous Graft-versus-Host Disease in Mice. Biology of blood and marrow transplantation. Biol Blood Marrow Transplant. 2017 Jan;23(1):30-37. Published online 2016 Nov 1. doi:10.1016/j.bbmt.2016.10.022. PMID:27815049.

Junghans, RP, Ma, Q, Rathore, R, Gomes, EM, Bais, AJ, Lo, AS, Abedi, M, Davies, RA, Cabral, HJ, Al-Homsi, AS, Cohen, SI. Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response. Prostate. 2016;76(14):1257-70. doi:10.1002/pros.23214. Epub 2016 Jun 21.

Steensma DP, Abedi M, Bejar R, Cogle CR, Foucar K, Garcia-Manero G, George TI, Grinblatt D, Komrokji R, Ma X, Maciejewski J, Pollyea DA, Savona MR, Scott B, Sekeres MA, Thompson MA, Swern AS, Nifenecker M, Sugrue MM, Erba H. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study. BMC Cancer. 2016 Aug 19;16:652. doi:10.1186/s12885-016-2710-6.

Stelling A, Jonas BA, Rashidi HH, Abedi M, Chen M. Acute Myeloid Leukemia with Isolated Trisomy 19 Associated with Diffuse Myelofibrosis and Osteosclerosis. Cancers (Basel). 2015 Dec 14;7(4):2459-65. doi:10.3390/cancers7040903. PMID:26694466.  PMCID:PMC4695903.

Park SS, Bauer G, Abedi M, Pontow S, Panorgias A, Jonnal R, Zawadzki RJ, Werner JS, Nolta J. Intravitreal autologous bone marrow CD34+ cell therapy for ischemic and degenerative retinal disorders: preliminary phase 1 clinical trial findings. Invest Ophthalmol Vis Sci. 2015 Dec 9;56(1):81-9. doi:10.1167/iovs.14-15415. PMID:25491299. PMCID:PMC4288143.

Barclay SL, Yang Y, Zhang S, Fong R, Barraza A, Nolta JA, Torbett BE, Abedi M, Bauer G, Anderson JS. Safety and efficacy of a tCD25 preselective combination anti-HIV lentiviral vector in human hematopoietic stem and progenitor cells. Stem Cells. 2015 Mar;33(3):870-9. PMID:25524029. DOI:10.1002/stem.1919.

Pai CC, Hsiao HH, Sun K, Chen M, Hagino T, Tellez J, Mall C, Blazar BR, Monjazeb A, Abedi M, Murphy WJ. Therapeutic benefit of bortezomib on acute graft-versus-host disease is tissue specific and is associated with interleukin-6 levels. Biol Blood Marrow Transplant. 2014 Dec;20(12):1899-904. doi:0.1016/j.bbmt.2014.07.022. Epub 2014 Jul 23. PMID:25064746. PMCID:PMC4254314.